Teva Products: Updated HCPCS Coding Information – 12/19/22

Teva Products: Updated HCPCS Coding Information
 

Updated HCPCS* Coding Information for Teva Products

Effective January 1, 2023, providers should use the new, permanently assigned HCPCS codes for these products, as shown in the tables below. Old/temporary HCPCS codes should not be used after December 31, 2022. Please update your claims processing system and any applicable coverage policies and fee schedules.†

Fosaprepitant for Injection

New HCPCS Code

Old HCPCS Code

Strength

Size

NDC Number

New HCPCS Code Description

J1456

J1453

150 mg/Vial

Single-Dose Vial

00591-4385-79

Injection, fosaprepitant (teva), not therapeutically equivalent to J1453, 1 mg

Fulvestrant Injection

New HCPCS Code

Old HCPCS Code

Strength

Size

NDC Number

New HCPCS Code Description

J9393

J9395

250 mg/5 mL (50 mg/mL)

2 Single-Dose Prefilled Syringes

00591-5019-02

Injection, fulvestrant (teva) not therapeutically equivalent to J9395, 25 mg

Pemetrexed Injection

New HCPCS Code

Old HCPCS Code

Strength

Size

NDC Number

New HCPCS Code Description

J9314

J9999 (temporary J code), J9305

1 g/40 mL

Single-Dose Vial

00480-4515-01

Injection, pemetrexed (teva) not therapeutically equivalent

to J9305, 10 mg

J9314

J9999 (temporary J code), J9305

100 mg/4 mL

Single-Dose Vial

00480-4516-01

Injection, pemetrexed (teva) not therapeutically equivalent

to J9305, 10 mg

J9314

J9999 (temporary J code), J9305

500 mg/20 mL

Single-Dose Vial

00480-4514-01

Injection, pemetrexed (teva) not therapeutically equivalent

to J9305, 10 mg

*Healthcare Common Procedure Coding System

†Note that specific guidance on the submission of the claims offered by the payer supersedes the codes listed, and providers are responsible for the accuracy of any claims, invoices, or related documentation submitted to payers.

© 2022 Teva Pharmaceuticals USA, Inc. TG-43288 December 2022